Trial Number
450-23
Conditions
Aortic Disease, Aortic Transection, Heart Disease, Heart Disease in Women, Heart Failure, Wounds
Participant Age Range
21 years and older
Participant Gender
Any
Enrolling Participants
Yes
Overview
“IMPRoving Outcomes in Vascular DisEase - Aortic Dissection”
The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.